Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke

Archives of Neurology

Volumn 61, Issue 6, 2004, Pages 889-892

  Rundek, Tatjana ^a   Naini, Ali ^a   Sacco, Ralph ^a   Coates, Kristen ^a   DiMauro, Salvatore ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UBIDECARENONE;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; ENZYME SYNTHESIS; EXERCISE TOLERANCE; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MYALGIA; MYOGLOBINURIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHABDOMYOLYSIS; SIDE EFFECT; STROKE;

AGED; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; UBIQUINONE;

EID: 2942587374     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.61.6.889     Document Type: Article

References (23)

1. Bliznakov EG, Wilkins DJ. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv Ther. 1998;15:218-228.
2. 10: the Baycol case - a modern Pandora's box. Biomed Pharmacother. 2002;56:56-59.
3. Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40:163-171.
4. 10. J Am Coll Nutr. 2001;20:591-598.
5. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-2382.
6. 10 deficiency. Neurology. 1997;48:1238-1243.
7. 10 deficiency. Neurology. 2001;57:515-518.
8. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87:8931-8934.
9. 10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137-S144.
10. 10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-229.
11. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57:62-66.
12. 10. Am Heart J. 2001;142:e2. Available at: http://www2.us.elsevierhealth.com/scripts/om.dll/serve?retrieve=/pii/ S0002870301528100&. Accessed March 12, 2004.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
14. 10 deficiency and the brain. Biofactors. 2003;18:145-152.
15. Evans M, Rees A. The myotoxicity of statins. Curr Opin Lipidol. 2002;13:415-420.
16. 10 deficiency. Neurology. 2001;56:849-855.
17. 10 deficiency. Neurology. 2003;60:1206-1208.
18. 10. Proc Natl Acad Sci U S A. 1985;82:4513-4516.
19. 10 in early Parkinson disease. Arch Neurol. 2002;59:1541-1550.
20. 10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341:201-204.
21. 10 and remacemide in Huntington's disease. Neurology. 2001;57:397-404.
22. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892-8897.
23. 10) in amyotrophic lateral sclerosis (ALS/MND) [abstract]. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;(suppl 3):119.